TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04102345

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavender Aromatherapy
Description: Commercially available lavender essential oil and diffuser.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem
Description: Physician directed, pre-prescribed. Study team does not prescribe zolpidem.
Study: NCT04547933

Intervention type: DIAGNOSTIC_TEST
Intervention: Bladder diary
Description: A 3-day bladder diary recording daily drinking fluid amount, daily urine amount, urgency and urinary incontinence episodes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bladder diary
Description: A 3-day bladder diary recording daily drinking fluid amount, daily urine amount, urgency and urinary incontinence episodes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bladder diary
Description: A 3-day bladder diary recording daily drinking fluid amount, daily urine amount, urgency and urinary incontinence episodes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bladder diary
Description: A 3-day bladder diary recording daily drinking fluid amount, daily urine amount, urgency and urinary incontinence episodes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bladder diary
Description: A 3-day bladder diary recording daily drinking fluid amount, daily urine amount, urgency and urinary incontinence episodes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bladder diary
Description: A 3-day bladder diary recording daily drinking fluid amount, daily urine amount, urgency and urinary incontinence episodes.
Study: NCT01215903

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish gelatin and omega-3 polyunsaturated fatty acid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acid
Study: NCT04055545

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HIIT
Description: * 5 min. warm up~* 10 × 60 seconds burst~* 60 seconds recovery after each burst~* Burst phase: HRR \>90%~* Recovery phase: HRR btw. 30-39%~* 5 min. cool down

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MICT
Description: * 5 min. warm up~* 20 min. continuous cycling: HRR btw. 40% - 59%~* 5 min. cool down
Study: NCT04087317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 Mg Oral Tablet
Description: The drug will be administrated when the woman arrive to the maternity unit, and every 6 hours thereafter, for first 24 hours following delivery.
Study: NCT04100044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Counseling
Description: Meet with physical therapist

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Receive personalized home exercise intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT04016064

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Er:YAG LASER, Nd:YAG laser, elctrosurgery, conventional surgery
Description: 1. Er: YAG laser (Fotana AT Fidelis III, Ljubljana, Slovenia) 200 mj, 10 Hz, 2 Watt and VLP (long pulse, 1000 μs); 1.3 mm diameter, 8 mm long cylindrical, a sapphire tip was used with air cooling and water irrigation.~2. Nd: YAG laser (Fotana AT Fidelis III, Ljubljana, Slovenia) was applied at 4 watts, 50 Hz, 300 μm microfiber tip and SP (short pulse: 180 μs) settings.~3. Electrosurgical (Servotome Classic System, High Frequency Surgical Equipment, Satelec, France).~4. Conventional surgical method was applied with hand instruments and gingivectomy knives.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Er:YAG LASER, Nd:YAG laser, elctrosurgery, conventional surgery
Description: 1. Er: YAG laser (Fotana AT Fidelis III, Ljubljana, Slovenia) 200 mj, 10 Hz, 2 Watt and VLP (long pulse, 1000 μs); 1.3 mm diameter, 8 mm long cylindrical, a sapphire tip was used with air cooling and water irrigation.~2. Nd: YAG laser (Fotana AT Fidelis III, Ljubljana, Slovenia) was applied at 4 watts, 50 Hz, 300 μm microfiber tip and SP (short pulse: 180 μs) settings.~3. Electrosurgical (Servotome Classic System, High Frequency Surgical Equipment, Satelec, France).~4. Conventional surgical method was applied with hand instruments and gingivectomy knives.
Study: NCT00583154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI-801
Description: Dose 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI-801
Description: Dose 4
Study: NCT04016610

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soliton's Acoustic Scar Reduction (SAR)
Description: Treatment of keloid scars for the temporary improvement in appearance.
Study: NCT02705963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Each tablet is 2mg trametinib to be taken orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Each tablet is 0.5mg trametinib to be taken orally once daily. 0.5mg tablets may be used if a dose reduction is required.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Contraceptive (1mg norethindrone, 0.035mg ethinyl estradiol)
Description: Combined oral contraceptive to be taken orally once daily.
Study: NCT04016064

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Er:YAG LASER, Nd:YAG laser, elctrosurgery, conventional surgery
Description: 1. Er: YAG laser (Fotana AT Fidelis III, Ljubljana, Slovenia) 200 mj, 10 Hz, 2 Watt and VLP (long pulse, 1000 μs); 1.3 mm diameter, 8 mm long cylindrical, a sapphire tip was used with air cooling and water irrigation.~2. Nd: YAG laser (Fotana AT Fidelis III, Ljubljana, Slovenia) was applied at 4 watts, 50 Hz, 300 μm microfiber tip and SP (short pulse: 180 μs) settings.~3. Electrosurgical (Servotome Classic System, High Frequency Surgical Equipment, Satelec, France).~4. Conventional surgical method was applied with hand instruments and gingivectomy knives.
Study: NCT02028143

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biosense Webster irrigated tip catheter
Description: The second group (study group) will have the ICE catheter placed through one of two existing 8F sheaths already in the left atrium. The ICE catheter will be exchanged in the sheath utilizing the lasso multipolar mapping catheter during left pulmonary vein ablation lines. During exchange, suction and irrigation techniques will be utilized to avoid any air or thrombus embolization. All patients will have standard anticoagulation during the procedure with heparin infusion adjusted to an activated clotting time (ACT) of 350-400. The left sided ICE catheter will be adjusted to visualize left sided structures, ablation tip and tissue interface, and adjacent noncardiac structures such as the esophagus during radiofrequency ablation of the left pulmonary vein system.
Study: NCT04087317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400Mg Tab
Description: The drug will be administrated when the woman arrive to the maternity unit, and every 6 hours thereafter, for first 24 hours following delivery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 Mg Oral Tablet
Description: The drug will be administrated after a maternal request, by at least 6 hours apart between dosages.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Description: The drug will be administrated after a maternal request, by at least 6 hours apart between dosages.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIR
Description: At any time, if a woman experienced pain despite the prescribed treatment, the next line of treatment was MIR (morphine immediate release, 10 mg tablet).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIR
Description: At any time, if a woman experienced pain despite the prescribed treatment, the next line of treatment was MIR (morphine immediate release, 10 mg tablet).
Study: NCT03559725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VLN menthol cigarettes (A)
Description: 0.4mg nicotine / g tobacco king size filter menthol cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VLN menthol cigarettes (A)
Description: 0.4mg nicotine / g tobacco king size filter menthol cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Brand Menthol Cigarettes (B)
Description: Usual brand king size menthol cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Brand Menthol Cigarettes (B)
Description: Usual brand king size menthol cigarettes
Study: NCT02028143

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biosense Webster irrigated tip catheter
Description: Group 1 will receive standard pulmonary vein isolation (PVI) procedure utilizing intracardiac guided ultrasound (ICE) placed within the right atrium via the femoral vein.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICE catheter placed through one of two existing 8F sheaths
Study: NCT01548287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5213
Description: AZD5213 doseA daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5213
Description: AZD5213 doseB daily
Study: NCT03559725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine gum (C)
Description: 4 mg nicotine gum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine gum (C)
Description: 4 mg nicotine gum
Study: NCT04522999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: The Valeda™ Light Delivery System
Study: NCT01841073

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Subjects will have 4 dietary counselling sessions in the first 9 weeks of the study with a goal to lose 5% of their body weight by week 9. They will be asked to maintain their weight loss until week 18.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cellulose
Description: Subjects will have 4 dietary counselling sessions in the first 9 weeks of the study with a goal to lose 5% of their body weight by week 9. They will be asked to maintain their weight loss until week 18.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Subject will take inulin for 6 weeks in total with no other change to their diet or lifestyle.
Study: NCT01548287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5213
Description: AZD5213 doseC daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet daily
Study: NCT02864602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV dexamethasone
Description: An infusion of IV dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV dexamethasone
Description: An infusion of IV dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV dexamethasone
Description: An infusion of IV dexamethasone
Study: NCT02842359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan/atorvastatin fixed dose combination
Description: Pharmaceutical form:Tablet Route of administration: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan SR47436
Description: Pharmaceutical form:Tablet Route of administration: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study: NCT04686214

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: heating
Description: patients were aggressively warmed using multiple heating methods such as pressurized air heater and intravenous fluid heater
Study: NCT04640857

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Silk'n Toothwave
Description: patients will receive a non-surgical treatment which will include oral hygiene instructions, calculus removal with ultrasonic and manual instruments. At the end of the meeting they will be provided with a toothbrush which is based on a radiofrequency technology.
Study: NCT04501822

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of clinical, instrumental and laboratory diagnostics tests
Description: During follow-up visits patients undergo clinical, instrumental and laboratory diagnostics tests
Study: NCT04632862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001
Description: DWP16001 A mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DWP16001
Description: DWP16001 A mg
Study: NCT02943161

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Citrulline
Description: The purpose of this study is to see if citrulline supplementation will restore NO levels and lung function in subjects with asthma.
Study: NCT00751231

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: Loading dose of 300mg or 600mg, followed by once daily dosing of 75 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRT060128
Description: 80-120 mg IV bolus administered prior to PCI, followed by twice daily dosing of oral 50mg, 100mg or 150mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRT060128
Description: 80-120 mg IV bolus administered prior to PCI, followed by twice daily dosing of oral 50mg, 100mg or 150mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRT060128
Description: 80-120 mg IV bolus administered prior to PCI, followed by twice daily dosing of oral 50mg, 100mg or 150mg
Study: NCT03562156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oteseconazole (VT-1161)
Description: Oteseconazole (VT-1161) 150mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo capsule
Study: NCT00864279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine Hydrochloride 10 mg tablets, single dose
Description: A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fast conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zyrtec® 10 mg tablets, single dose
Description: B: Active comparator Subjects received Pfizer Inc. formulated products under fast conditions
Study: NCT01623947

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Beverage
Description: 1400 ml flavored, colored, artificially sweetened, non-caloric beverage divided into 6 servings provided prior to and during the 2.5 hr interval ride.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 2.8 g Sustamine Beverage
Description: 1400 ml flavored, colored, artificially sweetened, beverage containing 2.8 g Sustamine divided into 6 servings provided prior to and during the 2.5 hr interval ride.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 19.6 g Sustamine Beverage
Description: 1400 ml flavored, colored, artificially sweetened, beverage containing 19.6 g Sustamine divided into 6 servings provided prior to and during the 2.5 hr interval ride.
Study: NCT01407601

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: daily supplementation of MK-7 over 6 weeks
Description: once daily intake of MK-7 prior to dialysis over 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: daily supplementation of MK-7 over 6 weeks
Description: once daily intake of MK-7 prior to dialysis over 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: daily supplementation of MK-7 over 6 weeks
Description: once daily intake of MK-7 prior to dialysis over 6 weeks
Study: NCT02687646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adult Allogeneic Mesenchymal cells from adipose tissue.
Description: Study treatment consists of Mesenchymal Stem Cell (MSC) derived from donors adipose tissue and expanded in vitro in a specific medium with platelet lysate without addition of animal derived products.~Subjects will receive four sequential IV dose of Mesenchymal stem cells.~Sequential doses:~Day 1: 0.7-1 x 106 MSC / kg Day 4: 0.7-1 x 106 MSC / kg Day 11: 0.7-1 x 106 MSC / kg Day 18: 0.7-1 x 106 MSC / kg
Study: NCT01721564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: 62.5 mg Bosentan twice a day for 1 month 125 mg Bosentan twice a day for 5 months
Study: NCT04252066

Intervention type: DRUG
Intervention: migalastat
Description: This is an observational study. Patients as described in Cohort 1 should have been exposed to at least 1 dose of migalastat during pregnancy and/or breastfeeding.
Study: NCT01841073

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cellulose
Description: Subject will take cellulose for 6 weeks in total with no other change to their diet or lifestyle.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Subject will take inulin for 6 weeks in total with no other change to their diet or lifestyle.~Subject will wear a Continuous Glucose Monitor for 4 x 5 days during the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cellulose
Description: Subject will take cellulose for 6 weeks in total with no other change to their diet or lifestyle.~Subject will wear a Continuous Glucose Monitor for 4 x 5 days during the study.
Study: NCT01287455

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 as BABY D3
Description: drops, 70 drops (= 14000 units), once weekly for 6 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: drops, 70 placebo drops, once weekly for 6 weeks
Study: NCT02020109

Intervention type: RADIATION
Intervention: splenic irradiation
Study: NCT01015924

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: plate osteosynthesis
Description: Patients are operated upon within 3 w of the fracture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: plate osteosynthesis
Description: Patients are operated upon within 3 w of the fracture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESIN
Description: Elastiv stable intramedullary nailing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESIN
Description: Elastiv stable intramedullary nailing
Study: NCT03884725

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fibrinogen Concentrate
Description: Fibrinogen Concentrate is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Subjects are to be given Fibrinogen Concentrate at an individually determined dose based on FIBTEM MCF and body weight as follows: (15 \[mm\] - MCF \[mm\]) \* body weight \[kg\] / 140 \[mm\*kg/g\] = gram fibrinogen to be dosed as Fibrinogen Concentrate. Fibrinogen Concentrate is to be infused over 1 to 2 minutes. After Fibrinogen Concentrate infusion, bleeding treatment will follow the predefined, standardized treatment regimen.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: 0.9% saline is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Patients randomized to the control group will receive the infusion of 0.9% saline (SF0,9%) prepared based on ROTEM measurement of maximum clot firmness (MCF). 0.9% saline is to be infused over 1 to 2 minutes. After 0.9% saline infusion, bleeding treatment will follow the predefined, standardized treatment regimen.
Study: NCT02438540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: metformin tablet 500 mg
Study: NCT03150914

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sirolimus
Description: mTOR inhibitor or placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: mTOR inhibitor or placebo
Study: NCT02699515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB0011359C
Description: Subjects with metastatic or locally advanced solid tumors received intravenous infusion of MSB0011359C over 1 hour once every two weeks for up to 12 months until confirmed progressive disease (PD), unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product (IMP) occurs.
Study: NCT02438540

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Description: metformin tablet 500 mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Electro body acupuncture and auricular acupuncture
Study: NCT01085578

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CG400549/placebo
Description: Period 1: a single oral dose of 80 mg CG400549 or placebo on Day 1 Period 2: a single oral dose of 320 mg CG400549 or placebo on Day 1 Period 3: a single oral dose of 1280 mg CG400549 or placebo on Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CG400549/placebo
Description: Period 1: a single oral dose of 160 mg CG400549 or placebo on Day 1 Period 2: a single oral dose of 640 mg CG400549 or placebo on Day 1 Period 3: a single oral dose of 1920 mg CG400549 or placebo on Day 1

Intervention type: DRUG
Group type: OTHER
Intervention: CG400549
Description: Period 1: a single oral dose of 640 mg CG400549 on Day 1 in the fasted state Period 2: a single oral dose of 640 mg CG400549 on Day 1 in the fed state
Study: NCT03245216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: Single-bout of moderate intensity aerobic exercise on a cycle ergometer before motor learning

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: rest
Description: Seated rest before motor learning

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motor learning
Description: Motor learning task on a stability platform (Stabilometer). Participants try to keep the tiltable platform in an horizontal position.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: motor learning
Description: Motor learning task on a stability platform (Stabilometer). Participants try to keep the tiltable platform in an horizontal position.
Study: NCT00402519

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated partial breast irradiation
Description: APBI with PDR and HDR brachytherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External beam whole breast irradiation
Description: Standard Whole breast irradiation
Study: NCT01269476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNX-001
Description: 3.6, 7.2, or 10.8 mg single dose or t.i.w.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same volumes and frequency as active.
Study: NCT04385095

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SNG001
Description: SNG001 via inhalation
Study: NCT04298840

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate Supplementation
Description: Participants in the creatine monohydrate supplementation arm will consume 5 grams per day of creatine monohydrate.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Supplementation
Description: Participants in the placebo supplementation arm will consume 5 grams per day of maltodextrin placebo.